Patents Assigned to Mikrogen Molekularbiologische Entwicklungs- GmbH
-
Patent number: 7083792Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: GrantFiled: January 22, 2004Date of Patent: August 1, 2006Assignee: Mikrogen Molekularbiologische Entwicklungs - GmbHInventors: Renate Fuchs, Bettina Wilske, Vera Preac-Mursic, Manfred Motz, Erwin Soutscheck
-
Publication number: 20040253611Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: ApplicationFiled: January 22, 2004Publication date: December 16, 2004Applicant: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Renate Fuchs, Bettina Wilske, Vera Preac-Mursic, Manfred Motz, Erwin Soutscheck
-
Patent number: 6808711Abstract: The present invention relates to immunologically active proteins from Borrelia burgdorferi which are present in a form which is free of other proteins derived from Borrelia burgdorferi and which exhibit the sequence of the protein 1829-22A, which has the amino acid sequence (SEQ. ID NO:1) MKKFNLIIEALFAILLTACNFGLMEETKIALESSSKDVKNKILQIKKDAE DKGVNFAAFTSSETGSKVTNGGLALREAKIQAINEVEKFLKRIEEEALKL KEHGNSGQFLELFDLLLEVLESLEPIGIKGLKDFISEEAKCNPISTSER LIEVKVQIENKMEEVKRKQNLNKERKSNKGKKKK or a part sequence therefor having at least 10 consecutive amino acids, or exhibit the sequence of the protein 1829-22B, which has the amino acid sequence (SEQ.Type: GrantFiled: March 26, 2003Date of Patent: October 26, 2004Assignee: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Manfred Motz, Erwin Soutschek
-
Patent number: 6753183Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: GrantFiled: November 7, 2002Date of Patent: June 22, 2004Assignee: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Renate Fuchs, Bettina Wilske, Vera Preac-Mursic, Manfred Motz, Erwin Soutscheck
-
Publication number: 20030185859Abstract: The present invention relates to immunologically active proteins from Borrelia burgdorferi which are present in a form which is free of other proteins derived from Borrelia burgdorferi and which exhibit the sequence of the protein 1829-22A, which has the amino acid sequence 1 MKKFNLIIEALFAILLTACNFGLMEETKIALESSSKDVKNKILQIKKDAE DKGVNFAAFTSSETGSKVTNGCLALREAKIQAINEVEKFLKRIEEEALKL KEHGNSGQFLELFDLLLEVLESLEPIGIKGLKDFIISEEAKCNPISTSER LIEVKVQIENKMEEVKRKQNLNKERKSNKGKKKKType: ApplicationFiled: March 26, 2003Publication date: October 2, 2003Applicant: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Manfred Motz, Erwin Soutschek
-
Patent number: 6610301Abstract: The present invention relates to immunologically active proteins from Borrelia burgdorferi which are present in a form which is free of other proteins derived from Borrelia burgdorferi and which exhibit the sequence of the protein 1829-22A, which has the amino acid sequence MKKFNLIIEALFAILLTACNFGLMEETKIALESSSKDVKNKILQIKKDAEDKGVNFAAFTSSETG SKVTNGGLALREAKIQAINEVEKFLKRIEEEALKLKEHGNSGQFLELFDLLLEVLESLEPIGIKG LKDFISEEAKCNPISTSERLIEVKVQIENKMEEVKRKQNLNKERKSNKGKKKK SEQ. ID NO.: 1 or a part sequence thereof having at least 10 consecutive amino acids, or exhibit the sequence of the protein 1829-22B, which has the amino acid sequence MIKYNKIILTLTLLASLLAACSLTGKARLESSVKDITNEIEKAIKEAEDAGVKTDAFTETQTGGK VAGPKIRAAKIRVADLTIKFLEATEEETITFKENGAGEDEFSGIYDLILNAAKAVEKIGMKDMTK TVEEAAKENPKTTANGIIEIVKVMKAKVENIKEKQTKNQK SEQ. ID NO.: 2 or a part sequence thereof having at least 10 consecutive amino acids.Type: GrantFiled: February 12, 1999Date of Patent: August 26, 2003Assignee: Mikrogen Molekularbiologische Entwicklungs - GmbHInventors: Manfred Motz, Erwin Soutschek
-
Publication number: 20030157562Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: ApplicationFiled: November 7, 2002Publication date: August 21, 2003Applicant: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Renate Fuchs, Bettina Wilske, Vera Preac-Mursic, Manfred Motz, Erwin Soutscheck
-
Patent number: 6509019Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: GrantFiled: November 13, 2000Date of Patent: January 21, 2003Assignee: Mikrogen Molekularbiologische Entwicklungs-GmbHInventors: Renate Fuchs, Bettina Wilske, Vera Preac-Mursic, Manfred Motz, Erwin Soutscheck
-
Patent number: 6274307Abstract: Immunologically active peptides or polypeptides with a partial amino-acid sequence of the capsid proteins VP1 and VP2 of parvovirus B19 which permit tests to be carried out at low cost, sensitively and specifically for the determination of antibodies against human parvovirus B19 are made available. Short peptide sequences which, employed as antigen, serve to identify anti-B19 IgG-positive sera are identified. Furthermore, the production of these peptides using genetic engineering measures is disclosed. Other antigens which are produced by genetic engineering and which can be stably produced in a high yield in E.coli and subsequently purified therefrom are used as additional antigens for IgG detection. Finally, a set of antigens permits tests to be carried out to determine IgM antibodies against the virus. In addition, the components, produced by genetic engineering, of the surface proteins represent substances which can be used for prophylactic immunisation.Type: GrantFiled: May 15, 1997Date of Patent: August 14, 2001Assignee: MIKROGEN molekularbiologische Entwicklungs-GmbHInventors: Erwin Soutschek, Manfred Motz
-
Patent number: 6183755Abstract: Various immunologically active proteins from Borrelia burgdorferi have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a B. burgdorferi gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation.Type: GrantFiled: November 19, 1998Date of Patent: February 6, 2001Assignee: Mikrogen Molekularbiologische Entwicklungs- GmbHInventors: Manfred Motz, Erwin Soutscheck, Renate Fuchs, Bettina Wilske, Vera Preac-Mursic